Patrick A Singleton

US Patent:

8518962, Aug 27, 2013

Filed:

Mar 12, 2010

Appl. No.:

12/723339

Inventors:

Jonathan Moss - Chicago IL, US
Mark Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US

Assignee:

The University of Chicago - Chicago IL

International Classification:

A01N 43/42
A61K 31/44
C07D 221/18

US Classification:

514282, 546 58

Abstract:

Embodiments of the invention provide methods of attenuating, e. g. , inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

US Patent:

8524731, Sep 3, 2013

Filed:

Apr 17, 2006

Appl. No.:

11/379010

Inventors:

Jonathan Moss - Chicago IL, US
Mark Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US

Assignee:

The University of Chicago - Chicago IL

International Classification:

A01N 43/42
A61K 31/44
C07D 221/18

US Classification:

514282, 546 58

Abstract:

The invention provides methods of attenuating, e. g. , inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

US Patent:

20080194611, Aug 14, 2008

Filed:

May 6, 2006

Appl. No.:

11/914984

Inventors:

John C. Alverdy - Glenview IL, US
Jonathan Moss - Chicago IL, US
Mark W. Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

International Classification:

A61K 31/485
A61K 31/445
A61P 31/00
A61P 17/00

US Classification:

514282, 514331

Abstract:

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), -mediated opthalmologic infection, -mediated otologic infection and -mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as . The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.

US Patent:

20080274119, Nov 6, 2008

Filed:

Mar 7, 2006

Appl. No.:

11/908058

Inventors:

Jonathan Moss - Chicago IL, US
Mark Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

Assignee:

THE UNIVERSITY OF CHICAGO - Chicago IL

International Classification:

A61K 39/395
C12N 5/06
A61K 31/439
A61P 35/00
A61P 3/10

US Classification:

4241451, 435375

Abstract:

The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

US Patent:

20100249064, Sep 30, 2010

Filed:

Sep 5, 2008

Appl. No.:

12/676793

Inventors:

Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

Assignee:

University of Chicago - Chicago IL

International Classification:

A61K 31/7008
A61P 9/10
A61P 9/00

US Classification:

514 62

Abstract:

The present invention concerns methods and compositions involving hyaluronan that has been substantially purified to enrich for hyaluronan with a molecular weight above 500 kilodaltons. This hyaluronan can be used for diseases and conditions characterized or caused by increased vascular permeability or angiogenesis. The higher molecular weight hyaluronan restores vascular integrity and inhibits angiogenesis in embodiments of the invention.

US Patent:

20110021551, Jan 27, 2011

Filed:

Mar 20, 2009

Appl. No.:

12/933784

Inventors:

Jonathan Moss - Chicago IL, US
Patrick A. Singleton - Chicago IL, US

International Classification:

A61K 31/485
A61K 31/436
A61P 37/00
A61P 35/00
A61P 19/02
A61P 3/10
A61P 25/00
A61P 17/00
C12N 5/02

US Classification:

514282, 514291, 435375

Abstract:

Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a μ-opioid receptor antagonist.

US Patent:

20120316190, Dec 13, 2012

Filed:

May 30, 2012

Appl. No.:

13/483932

Inventors:

John C. Alverdy - Glenview IL, US
Jonathan Moss - Chicago IL, US
Mark W. Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

Assignee:

THE UNIVERSITY OF CHICAGO - CHICAGO IL

International Classification:

A61K 31/485
A61P 1/00

US Classification:

514282

Abstract:

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., inflammatory bowel disease. Methods of reducing the symptoms of inflammatory bowel disease and the risk of developing inflammatory bowel disease are also provided.

US Patent:

20140011831, Jan 9, 2014

Filed:

Aug 21, 2013

Appl. No.:

13/972129

Inventors:

Mark Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

Assignee:

The University of Chicago - Chicago IL

International Classification:

A61K 31/485
G01N 33/50
A61K 31/452

US Classification:

514282, 514331, 435 29, 435 71

Abstract:

Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.